• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Editas Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    5/14/25 7:06:56 AM ET
    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EDIT alert in real time by email
    edit-20250514
    0001650664FALSE00016506642025-05-142025-05-14

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _________________________________________________________________________________________
    FORM 8-K
    _________________________________________________________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 14, 2025
    _________________________________________________________________________________________
    Editas Medicine, Inc.
    (Exact Name of Registrant as Specified in its Charter)
    _________________________________________________________________________________________
    Delaware001-3768746-4097528
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
    11 Hurley Street

    Cambridge,
    Massachusetts02141
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s telephone number, including area code: (617) 401-9000
    (Former Name or Former Address, if Changed Since Last Report)
    __________________________________________________________________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.0001 par value per shareEDITThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 7.01    Regulation FD Disclosure.
    On May 14, 2025, Editas Medicine, Inc. (the “Company”) issued a press releases titled “Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting,” a copy of which is furnished as Exhibit 99.1 hereto.
    The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
    Item 8.01 Other Events.
    On May 14, 2025, the Company announced new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (“HSCs”) with a single dose of proprietary targeted lipid nanoparticle (“tLNP”) in humanized mice and non-human primates (“NHPs”).
    In these studies, the Company’s proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells and/or HSCs in humanized mice (mice engrafted with human CD34+ cells) and in NHPs. In an ongoing NHP study, administration of a single intravenous dose of the Company’s proprietary tLNP demonstrated high efficiency HSC delivery and achieved up to 47% HBG1/2 editing levels. In a study with humanized mice, administration of a single dose achieved 48% editing of HBG1/2 in long-term HSCs. Both studies exceeded the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, preliminary biodistribution data in NHPs with the Company’s tLNP shows significant de-targeting of the liver in contrast to standard LNPs.
    Item 9.01    Financial Statements and Exhibits.
    (d)Exhibits
    Exhibit
    No.
    Description
    99.1
    Press release issued by the Company on May 14, 2025*
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)
    *This exhibit shall be deemed to be furnished and not filed.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    EDITAS MEDICINE, INC.
    Date: May 14, 2025By:/s/ Amy Parison
    Amy Parison
    Chief Financial Officer

    Get the next $EDIT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDIT

    DatePrice TargetRatingAnalyst
    4/28/2025$3.00Buy
    H.C. Wainwright
    12/16/2024Neutral → Underweight
    Analyst
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    12/13/2024Buy → Hold
    Truist
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    12/11/2024$7.00 → $4.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024$13.00 → $1.00Buy → Underperform
    BofA Securities
    11/6/2024In-line → Outperform
    Evercore ISI
    More analyst ratings

    $EDIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

      Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated ap

      6/12/25 2:01:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

      Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy. Key deliv

      5/14/25 9:31:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

      Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in humanized mice and non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clin

      5/14/25 7:01:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    SEC Filings

    See more
    • Editas Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      6/12/25 6:28:39 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      6/2/25 5:28:58 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      5/14/25 7:06:56 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care